Business Wire

ENRY’S-ISLAND

17.5.2022 16:02:10 CEST | Business Wire | Press release

Share
Enry’s Island Secures €20 Million from LDA Capital to Scale the First Accelerator in the Metaverse

Enry’s Island is delighted to announce that they have secured a Euro 20 million capital commitment from LDA Capital , an alternative investment group with expertise in complex, cross-border transactions around the globe, based in Los Angeles, California. Adding to the year’s success, this capital commitment comes just as Enry’s Island prepares to operate on international markets, making them a rising star in the incubation and acceleration world, one of the hottest industries of this current economic environment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517005729/en/

“We are excited about our partnership with LDA Capital”, says Luigi Valerio Rinaldi, founder and CEO of Enry’s Island. Over the course of the next few months, the Company will transform into a “S.p.a.” (Italian joint stock company), “allowing the business to scale even faster with LDA’s flexible financing package. We are sure that the relationship with LDA will continue in a mutually gratifying way in the medium and long term horizon, allowing the horses in our stable to become unicorns.”

This new capital commitment of funding will be used to scale Enry’s Island phygital capabilities. Specifically, the areas that the company will focus on are:

  • Expansion in the Metaverse and physical spaces (thanks to Enry’s Island portfolio company Rinascimento 5 )
  • International reach increase, thanks to Enry’s Island Local Companies
  • Add 12x to 36x financial value within 3-5 years
  • Consolidating a worldwide standard protocol for the assessment and evaluation of the startups, based on Enry’s Model intellectual property (IP)

At the forefront of the industry, Enry’s Island is the first Incubation & Acceleration Metaverse (# 1 incubator & accelerator in Italy, & # 6 in Europe according to Crunchbase Q4/2021), with local companies in US, UK, Italy, Spain, Ireland, Africa, a global community of more than 800 stakeholders who include entrepreneurs, investors, and professionals and 30 startups, thoroughly assessed and evaluated based on Enry’s Model, the patented intellectual property the whole organization, processes and tool of Enry’s Island is based on. The Enry’s Model is also part of the “Enry’s Theory ” manual of business management, published by MacGraw-Hill .

About LDA Capital

LDA Capital is a global alternative investment group with expertise in cross border transactions worldwide. Our team has dedicated their careers to international & cross border opportunities having collectively executed over 250 transactions in both the public and private middle markets across 43 countries with aggregate transaction values of over US$11 billion. For more information please visit: www.ldacap.com ; For inquires please email: info@ldacap.com .

About Enry’s Island

  • 15 years of experience in the management of very early stage startups, with a mortality rate of only 10% (against 90% which is the industry average)
  • 12-month incubation and acceleration programs, totally customized to the needs of startups, with investments of € 200k in operational services (not just mentorship)
  • Proprietary patent, Enry's Model , which allows for the evaluation of company performance and value; Enry's Model is also the subject of a McGrawHill manual (which, in view of its success in Europe, has been translated for the US market);
  • Explosive scale up in the last 3 years, going from 8 to 25 companies, from €2M to €40M in portfolio value, from a community of 30 to 800 stakeholders;
  • full remote and totally distributed organization, which has allowed Enry’s Island to grow during the last 2 years of pandemic;
  • A revolutionary corporate architecture, which includes local companies in Ita, US, UK, Africa, Ibiza, Ireland and upcoming openings in the Far East, that do not replicate, but specialize and scale the different EI best practices in the different countries.
  • High information symmetry, given that the whole EI community uses a revolutionary Saas platform (hui.land), which guarantees efficiency and effectiveness in business management and business risk containment; HUI provides KPIs to all internal and external stakeholders, allowing investors to invest directly in target companies through HUI (thanks to crowdfunding campaigns in Europe, US and Canada), directly through HUI;
  • A revolutionary vision and management of space, both physical (having eliminated any physical location, as if it were in a DAO, but using a network of hosts with ideal characteristics for remote working in places with a high quality of life, such as villages, natural areas) and metaverse space (EI has started investing in the metaverse, building its first building in Cryptovoxels and having launched the first investor day entirely in metaverse https://www.cryptovoxels.com/parcels/7328 )

Visit www.enrysisland.com and discover why Enry’s Island has ignited interest from all over the world.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye